(Q37603371)

21 August 2017

1 reference

title

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition (English)

1 reference

21 August 2017

4

Mark D Gorrell

1 reference

21 August 2017

Mark Kirby

1

1 reference

21 August 2017

Denise M T Yu

series ordinal

2

1 reference

21 August 2017

Steven O'Connor

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

28 September 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

118

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

31-41

1 reference

DPP-4 inhibitors and their potential role in the management of type 2 diabetes

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Beta cell mass in diabetes: a realistic therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Fibroblast activation protein and chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

The biology of chemokines and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Unchanged signaling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

Dipeptidyl peptidase 8/9-like activity in human leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090047

21 January 2018

Identifiers

DOI

10.1042/CS20090047

1 reference

release_jd7wiypd6bdxpg7unwtwc2ikg4

21 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jd7wiypd6bdxpg7unwtwc2ikg4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference